Fasting and medical issues during Ramadan.

1. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344: 1888-1894. 2. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488-1497. 3. Schneider DJ, Herrmann HC, Lakkis N, et al. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol. 2003;91:334-336. 4. Sorajja P, Gersh BJ, Costantini C, et al. Combined prognostic utility of STsegment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. Eur Heart J. 2005;26:667-674. 5. Arshad A. Angiojet rheolytic thrombectomy in patients undergoing primary angioplasty for acute myocardial infarction [oral abstract]. Presented at: Transcatheter Therapeutics Convention; September 27-October 1, 2004; Washington, DC. 6. Stone GW, Webb J, Cox DA, et al; Enhanced Myocardial Efficacy and Recovery by Aspiration of Liberated Debris (EMERALD) Investigators. Distal microcirculatory protection during percutaneous coronary intervention in acute STsegment elevation myocardial infarction: a randomized controlled trial. JAMA. 2005; 293:1063-1072.